Alflutinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with specific genetic mutations. It is an EGFR tyrosine kinase inhibitor, targeting and blocking the activity of the epidermal growth factor receptor, which is often mutated in certain types of lung cancer. By inhibiting this receptor, alflutinib helps to slow down or stop the growth of cancer cells. It is especially effective in cases where the cancer has developed resistance to first-generation EGFR inhibitors. The drug is administered orally, making it convenient for patients, and is often used as part of a targeted therapy regimen to improve outcomes and quality of life for individuals with advanced or metastatic NSCLC.